1. Home
  2. NBIX
  3. NBIX News

Latest Neurocrine Biosciences Inc. (NBIX) News on September 13, 2025

NBIX

MT Newswires

8 days ago

RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating

High Growth Tech Stocks To Watch In The US August 2025
NBIX

Simply Wall St.

23 days ago

High Growth Tech Stocks To Watch In The US August 2025

GRFS or NBIX: Which Is the Better Value Stock Right Now?
NBIX

Zacks

23 days ago

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
NBIX

Zacks

a month ago

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus

High Growth Tech Stocks In US To Watch July 2025
NBIX

Simply Wall St.

2 months ago

High Growth Tech Stocks In US To Watch July 2025

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NBIX

Zacks

2 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NBIX

MT Newswires

2 months ago

Truist Securities Initiates Coverage on Neurocrine Biosciences With Buy Rating, $163 Price Target

Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $135.00

CPRX vs. NBIX: Which Stock Is the Better Value Option?
NBIX

Zacks

3 months ago

CPRX vs. NBIX: Which Stock Is the Better Value Option?

Exploring 3 High Growth Tech Stocks In The US Market
NBIX

Simply Wall St.

3 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

NBIX

Argus Research

3 months ago

NBIX: What does Argus have to say about NBIX?

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Names Lewis Choi as Chief Information Officer

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

CPRX or NBIX: Which Is the Better Value Stock Right Now?
NBIX

Zacks

3 months ago

CPRX or NBIX: Which Is the Better Value Stock Right Now?

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
NBIX

GlobeNewswire

3 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched
NBIX

Insider Monkey

3 months ago

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched

NBIX

MT Newswires

3 months ago

Neurocrine Reports Positive Data in Mid-Stage Schizophrenia Trial

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Exploring 3 High Growth Tech Stocks In The US Market
NBIX

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In The US Market

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

GRFS or NBIX: Which Is the Better Value Stock Right Now?
NBIX

Zacks

4 months ago

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

NBIX

Argus Research

4 months ago

NBIX: Lowering target price to $123.00

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential
NBIX

Insider Monkey

4 months ago

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality
NBIX

Simply Wall St.

4 months ago

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NBIX

Simply Wall St.

4 months ago

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
NBIX

Simply Wall St.

4 months ago

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday
NBIX

Insider Monkey

4 months ago

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday

NBIX

Argus Research

4 months ago

NBIX: Raising target price to $125.00

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
NBIX

Investor's Business Daily

4 months ago

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

NBIX

MT Newswires

4 months ago

BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating

NBIX

MT Newswires

4 months ago

UBS Adjusts Price Target on Neurocrine Biosciences to $152 From $137, Buy Rating Kept

NBIX

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Neurocrine Biosciences Inc Earnings Call

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

NBIX

MT Newswires

4 months ago

RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating

NBIX

GuruFocus.com

4 months ago

Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ...

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
NBIX

Zacks

4 months ago

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
NBIX

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Q1 Non-GAAP Earnings Fall, Sales Rise; Maintains 2025 Guidance

NBIX

Associated Press Finance

4 months ago

Neurocrine: Q1 Earnings Snapshot

Neurocrine begins Phase III programme for schizophrenia treatment
NBIX

Clinical Trials Arena

4 months ago

Neurocrine begins Phase III programme for schizophrenia treatment

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential
NBIX

Insider Monkey

4 months ago

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Starting Phase 3 Trial of Prospective Schizophrenia Medication

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NBIX

Zacks

4 months ago

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?
NBIX

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Exploring 3 High Growth Tech Stocks In The US Market
NBIX

Simply Wall St.

5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

NBIX

Argus Research

5 months ago

NBIX: Raising target price to $107.00

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case
NBIX

Simply Wall St.

5 months ago

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case

NBIX

Argus Research

5 months ago

NBIX: Raising target price to $101.00

NBIX

MT Newswires

5 months ago

Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says

NBIX

MT Newswires

5 months ago

RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138

NBIX

Argus Research

5 months ago

NBIX: Lowering target price to $92.00

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
NBIX

Zacks

5 months ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Appoints New Chief Medical Officer

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

NBIX

MT Newswires

5 months ago

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating

NBIX

MT Newswires

5 months ago

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating

NBIX

MT Newswires

5 months ago

RBC Trims Price Target on Neurocrine Biosciences to $138 From $139, Keeps Sector Perform Rating

NBIX

Argus Research

5 months ago

NBIX: Lowering target price to $112.00

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

NBIX

Argus Research

6 months ago

NBIX: Raising target price to $122.00

Exploring High Growth Tech Stocks in US for March 2025
NBIX

Simply Wall St.

6 months ago

Exploring High Growth Tech Stocks in US for March 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
NBIX

Clinical Trials Arena

6 months ago

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires
NBIX

Insider Monkey

6 months ago

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
NBIX

The Wall Street Journal

6 months ago

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

NBIX

MT Newswires

6 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions
NBIX

Simply Wall St.

6 months ago

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
NBIX

Clinical Trials Arena

6 months ago

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
NBIX

PR Newswire

6 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

NBIX

Argus Research

6 months ago

NBIX: Lowering target price to $119.00

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
NBIX

PR Newswire

7 months ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

NBIX

Argus Research

7 months ago

NBIX: Raising target price to $122.00

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
NBIX

PR Newswire

7 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

High Growth Tech Stocks To Watch In February 2025
NBIX

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In February 2025

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?
NBIX

Insider Monkey

7 months ago

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest
NBIX

Simply Wall St.

7 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

NBIX

MT Newswires

7 months ago

Sector Update: Health Care Stocks Mixed Premarket Friday

NBIX

MT Newswires

7 months ago

Neurocrine Biosciences Approves $500 Million Share Repurchase Program

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
NBIX

PR Newswire

7 months ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

NBIX

Argus Research

7 months ago

NBIX: Lowering target price to $120.00

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January
NBIX

Insider Monkey

7 months ago

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

NBIX

MT Newswires

7 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing

NBIX

MT Newswires

7 months ago

Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Hold Rating, $138 Price Target

Share on Social Networks: